FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912782643> ?p ?o ?g. }

• W2912782643 endingPage "S343" @default.
• W2912782643 startingPage "S342" @default.
• W2912782643 abstract "Introduction: Patient-reported outcomes (PROs) are important measures to assess response in patients with IBD. Vedolizumab (VDZ) is a gut-selective monoclonal antibody that specifically binds α 4β7 integrin and blocks gut lymphocyte trafficking, and is approved for use in moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) patients who are naïve or have previously been exposed to tumor necrosis factor antagonists (anti-TNFs). Less is known about the real-world experience of patients on VDZ for changes in PROs. Methods: We performed a prospective cohort study investigating changes in PROs within the CCFA Partners cohort. All patients with CD or UC initiating VDZ from 2014 to present who had at least 6 months of follow-up were included. We stratified by biologic anti-TNF naïve (BN) or biologic anti-TNF exposed (BE) status. Outcomes included the short inflammatory bowel diseases questionnaire (SIBDQ); PRO measurement information system (PROMIS) assessing anxiety, depression, fatigue, social satisfaction, sleep disturbance, and pain interference; and the short CD activity index (sCDAI) as a measure of clinical remission. Bivariate analyses were performed to describe differences by BN or BE status; PRO changes were analyzed. Results: VDZ was initiated in 348 patients with CD and 169 with UC. The majority of CD (54%) and UC patients (65%) were managed in private practice settings (Table 1). A total of 20 (6%) CD patients and 32 (19%) UC patients were BN. CD patients who were BE had higher rates of prior surgery (67%) than BN patients (37%, p=0.01); BE UC patients had higher rates of prior hospitalization (72%) than BN patients (28%, p < 0.01). In the overall IBD population, corticosteroid-free remission (CSFR) rates as defined by sCDAI at 6-12 months improved from 20% to 45% in BN patients (difference 25%, p=0.03) vs improvement of 24% to 30% in BE patients (difference 6%, p=0.13). BN patients experienced greater improvements in PROs than BE patients, with significant improvement in social satisfaction (p=0.03) (Table 2). Multiple PRO domains met minimally clinically important differences at follow-up for BN patients.Table: No Caption availableTable: No Caption availableConclusion: VDZ was predominantly used in individuals with prior BE in this real-world cohort. CSFR rates and social satisfaction were significantly improved in BN patients after VDZ. Trends toward minimally clinically important differences in multiple additional PRO domains were also noted in BN patients." @default.
• W2912782643 created "2019-02-21" @default.
• W2912782643 creator A5009813930 @default.
• W2912782643 creator A5030884630 @default.
• W2912782643 creator A5031292783 @default.
• W2912782643 creator A5060843899 @default.
• W2912782643 creator A5071230912 @default.
• W2912782643 creator A5072441252 @default.
• W2912782643 date "2017-10-01" @default.
• W2912782643 modified "2023-10-14" @default.
• W2912782643 title "Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD)" @default.
• W2912782643 doi "https://doi.org/10.14309/00000434-201710001-00624" @default.
• W2912782643 hasPublicationYear "2017" @default.
• W2912782643 type Work @default.
• W2912782643 sameAs 2912782643 @default.
• W2912782643 citedByCount "0" @default.
• W2912782643 crossrefType "journal-article" @default.
• W2912782643 hasAuthorship W2912782643A5009813930 @default.
• W2912782643 hasAuthorship W2912782643A5030884630 @default.
• W2912782643 hasAuthorship W2912782643A5031292783 @default.
• W2912782643 hasAuthorship W2912782643A5060843899 @default.
• W2912782643 hasAuthorship W2912782643A5071230912 @default.
• W2912782643 hasAuthorship W2912782643A5072441252 @default.
• W2912782643 hasConcept C126322002 @default.
• W2912782643 hasConcept C139719470 @default.
• W2912782643 hasConcept C162324750 @default.
• W2912782643 hasConcept C17991360 @default.
• W2912782643 hasConcept C188816634 @default.
• W2912782643 hasConcept C2776207728 @default.
• W2912782643 hasConcept C2776215756 @default.
• W2912782643 hasConcept C2776867660 @default.
• W2912782643 hasConcept C2777138892 @default.
• W2912782643 hasConcept C2778260677 @default.
• W2912782643 hasConcept C2778271842 @default.
• W2912782643 hasConcept C2779134260 @default.
• W2912782643 hasConcept C2779280984 @default.
• W2912782643 hasConcept C2780479503 @default.
• W2912782643 hasConcept C71924100 @default.
• W2912782643 hasConcept C72563966 @default.
• W2912782643 hasConcept C90924648 @default.
• W2912782643 hasConceptScore W2912782643C126322002 @default.
• W2912782643 hasConceptScore W2912782643C139719470 @default.
• W2912782643 hasConceptScore W2912782643C162324750 @default.
• W2912782643 hasConceptScore W2912782643C17991360 @default.
• W2912782643 hasConceptScore W2912782643C188816634 @default.
• W2912782643 hasConceptScore W2912782643C2776207728 @default.
• W2912782643 hasConceptScore W2912782643C2776215756 @default.
• W2912782643 hasConceptScore W2912782643C2776867660 @default.
• W2912782643 hasConceptScore W2912782643C2777138892 @default.
• W2912782643 hasConceptScore W2912782643C2778260677 @default.
• W2912782643 hasConceptScore W2912782643C2778271842 @default.
• W2912782643 hasConceptScore W2912782643C2779134260 @default.
• W2912782643 hasConceptScore W2912782643C2779280984 @default.
• W2912782643 hasConceptScore W2912782643C2780479503 @default.
• W2912782643 hasConceptScore W2912782643C71924100 @default.
• W2912782643 hasConceptScore W2912782643C72563966 @default.
• W2912782643 hasConceptScore W2912782643C90924648 @default.
• W2912782643 hasLocation W29127826431 @default.
• W2912782643 hasOpenAccess W2912782643 @default.
• W2912782643 hasPrimaryLocation W29127826431 @default.
• W2912782643 hasRelatedWork W1576589857 @default.
• W2912782643 hasRelatedWork W2183184031 @default.
• W2912782643 hasRelatedWork W2375484873 @default.
• W2912782643 hasRelatedWork W2605454453 @default.
• W2912782643 hasRelatedWork W2794344940 @default.
• W2912782643 hasRelatedWork W3177272123 @default.
• W2912782643 hasRelatedWork W3205942131 @default.
• W2912782643 hasRelatedWork W4226137497 @default.
• W2912782643 hasRelatedWork W52633626 @default.
• W2912782643 hasRelatedWork W79702259 @default.
• W2912782643 hasVolume "112" @default.
• W2912782643 isParatext "false" @default.
• W2912782643 isRetracted "false" @default.
• W2912782643 magId "2912782643" @default.
• W2912782643 workType "article" @default.